Rod MacKenzie, PhD, is chief development officer and executive vice president for Pfizer. Rod leads the global product development organization, which is responsible for the clinical development and advancement of Pfizer's pipeline of innovative medicines in inflammation and immunology, internal medicine, hospital, oncology and rare disease, as well as regulatory affairs in support of Pfizer's R&D pipeline and portfolio of marketed therapies. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximizing the return on R&D investment across the Pfizer portfolio, and is a member of Pfizer's executive leadership team.
Rod joined Pfizer in Sandwich, UK as a research ccientist and conducted medicinal chemistry research in the cardiovascular, GI, sexual health, urology and allergy and respiratory diseases. Rod is the co-inventor of darifenacin (Enablex™). Rod has held numerous leadership positions at Pfizer, including head of pharmatherapeutics research and development where he oversaw the cardiovascular and metabolic diseases, pain and sensory disorders and neuroscience research units and was responsible for all medicinal chemistry at Pfizer, as well as small molecule pharmaceutical sciences, pharmacokinetics, dynamics and metabolism and comparative medicine. He also served as site director of the Groton, Connecticut laboratories, Pfizer's largest global R&D facility. Prior to this role, Rod held a series of research leadership positions, including senior vice president and head of worldwide research, head of discovery chemistry in Sandwich, UK, head of the Discovery Technology Center in Cambridge, Massachusetts, head of discovery research in Ann Arbor, Michigan, and head of drug safety R&D.
Rod represents Pfizer on the board of directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV. He also represents Pfizer on the board of directors for TransCelerate, a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies.
Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition with Professor W.C. Still.
Rod will be honored at the 31st annual Woman of the Year on Wednesday, 29 April at the New York Marriott Marquis where nearly 2,500 leaders from across the industry will attend. The event will also recognize the HBA Woman of the Year, STAR and nearly 100 Rising Stars and Luminaries from across the spectrum of our industry.